Amphotericin B formulations: a comparative review of efficacy and toxicity (Q38111293)

29 August 2017

Amphotericin B formulations: a comparative review of efficacy and toxicity (English)

1 reference

29 August 2017

1 reference

Richard J Hamill

1

1 reference

29 August 2017

1 June 2013

1 reference

29 August 2017

1 reference

29 August 2017

73

1 reference

29 August 2017

9

1 reference

29 August 2017

919-934

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-013-0069-4

29 August 2017

0 references

cites work

Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis

1 reference

12 December 2020

Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial

1 reference

12 December 2020

In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains

1 reference

12 December 2020

Update on the genus Trichosporon

1 reference

12 December 2020

High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance.

1 reference

12 December 2020

In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole.

1 reference

12 December 2020

A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.

1 reference

12 December 2020

Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients

1 reference

12 December 2020

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

1 reference

12 December 2020

Equilibrium binding of amphotericin B and its methyl ester and borate complex to sterols

1 reference

12 December 2020

In vitro and in vivo antifungal activity of amphotericin B lipid complex: are phospholipases important?

1 reference

12 December 2020

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

1 reference

12 December 2020

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

12 December 2020

Amphotericin B activation of human genes encoding for cytokines

1 reference

12 December 2020

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

1 reference

12 December 2020

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

1 reference

12 December 2020

Overview of the lipid formulations of amphotericin B.

1 reference

12 December 2020

Comparative capacity of four antifungal agents to stimulate murine macrophages to produce tumour necrosis factor alpha: an effect that is attenuated by pentoxifylline, liposomal vesicles, and dexamethasone

1 reference

12 December 2020

Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4.

1 reference

12 December 2020

Variability in Polyene Content and Cellular Toxicity Among Deoxycholate Amphotericin B Formulations

1 reference

12 December 2020

Lipid-based amphotericin B: a review of the last 10 years of use.

1 reference

12 December 2020

Amphotericin B lipid preparations: what are the differences?

1 reference

12 December 2020

Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B

1 reference

12 December 2020

Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study

1 reference

12 December 2020

Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis

1 reference

12 December 2020

Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity

1 reference

12 December 2020

Lipid formulations of amphotericin B: recent progress and future directions

1 reference

12 December 2020

Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B.

1 reference

12 December 2020

The use of amphotericin B to detect inhibitors of cellular cholesterol biosynthesis.

1 reference

12 December 2020

Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content

1 reference

12 December 2020

The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism

1 reference

12 December 2020

1 reference

12 December 2020

Safety and efficacy of amphotericin B colloidal dispersion. An overview

1 reference

12 December 2020

Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion.

1 reference

12 December 2020

Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia

1 reference

12 December 2020

Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS

1 reference

12 December 2020

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

1 reference

12 December 2020

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits

1 reference

12 December 2020

Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia

1 reference

12 December 2020

Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety

1 reference

12 December 2020

Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis

1 reference

12 December 2020

Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system

1 reference

12 December 2020

Leishmaniasis impact and treatment access

1 reference

12 December 2020

Amphotericin B colloidal dispersion. Pre-clinical review

1 reference

12 December 2020

AmBisome (liposomal amphotericin B): a comparative review.

1 reference

12 December 2020

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

1 reference

12 December 2020

Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens

1 reference

12 December 2020

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

12 December 2020

Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature

1 reference

12 December 2020

Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006.

1 reference

12 December 2020

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

1 reference

12 December 2020

The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012.

1 reference

12 December 2020

Fungal phospholipase activity and susceptibility to lipid preparations of amphotericin B

1 reference

12 December 2020

Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species.

1 reference

12 December 2020

Diversity of lipid-based polyene formulations and their behavior in biological systems

1 reference

12 December 2020

Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies

1 reference

12 December 2020

Selective toxicity and enhanced therapeutic index of liposomal polyene antibiotics in systemic fungal infections

1 reference

12 December 2020

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?

1 reference

12 December 2020

Pretreatment regimens for adverse events related to infusion of amphotericin B.

1 reference

12 December 2020

Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)

1 reference

12 December 2020

Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.

1 reference

12 December 2020

Immunocompromised hosts: immunopharmacology of modern antifungals.

1 reference

12 December 2020

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

12 December 2020

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

1 reference

12 December 2020

The lipid formulations of amphotericin B.

1 reference

12 December 2020

Amphotericin B: 30 years of clinical experience

1 reference

12 December 2020

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

1 reference

12 December 2020

Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties.

1 reference

12 December 2020

Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis

1 reference

12 December 2020

Lipid-based amphotericin B for the treatment of fungal infections

1 reference

12 December 2020

Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate

1 reference

12 December 2020

Mortality and costs of acute renal failure associated with amphotericin B therapy

1 reference

12 December 2020

Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans.

1 reference

12 December 2020

Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis

1 reference

12 December 2020

Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections

1 reference

12 December 2020

Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial

1 reference

12 December 2020

Trichosporon beigelii, an emerging pathogen resistant to amphotericin B

1 reference

12 December 2020

Bloodstream infections due to Trichosporon spp.: species distribution, Trichosporon asahii genotypes determined on the basis of ribosomal DNA intergenic spacer 1 sequencing, and antifungal susceptibility testing.

1 reference

12 December 2020

Liposomal amphotericin B for the treatment of visceral leishmaniasis

1 reference

12 December 2020

Lipid formulations of amphotericin B: clinical efficacy and toxicities

1 reference

12 December 2020

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

1 reference

12 December 2020

Biological activity of polyene antibiotics

1 reference

12 December 2020

10.1007/S40265-013-0069-4

Identifiers

DOI

1 reference

PubMed ID

23729001

Dimensions Publication ID

29 August 2017

1034177761

0 references

Fatcat ID

release_7pqq74z76nbabbub73tfzpr7z4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7pqq74z76nbabbub73tfzpr7z4

24 November 2022

mapped directly with Wikidata item

PubMed ID

23729001

1 reference

PubMed ID

23729001